1
|
Lebreton L, Hennart B, Baklouti S, Trimouille A, Boyer JC, Becquemont L, Dhaenens CM, Picard N. [Pharmacogenetics of aminoglycoside ototoxicity: State of knowledge and practices - Recommendations of the Francophone Network of Pharmacogenetics (RNPGx)]. Therapie 2024:S0040-5957(24)00068-4. [PMID: 38876950 DOI: 10.1016/j.therap.2024.05.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2023] [Revised: 05/07/2024] [Accepted: 05/23/2024] [Indexed: 06/16/2024]
Abstract
The administration of aminoglycosides can induce nephrotoxicity or ototoxicity, which can be monitored through pharmacological therapeutic drug monitoring. However, there are cases of genetic predisposition to ototoxicity related to the MT-RNR1 gene, which may occur from the first administrations. Pharmacogenetic analysis recommendations have recently been proposed by the Clinical Pharmacogenetics Implementation Consortium (CPIC). The Francophone Pharmacogenetics Network (RNPGx) provides a bibliographic synthesis of this genetic predisposition, as well as professional recommendations. The MT-RNR1 gene codes for mitochondrial 12S rRNA, which constitutes the small subunit of the mitochondrial ribosome. Three variants can be identified: the variants m.1555A>G and m.1494C>T of the MT-RNR1 gene have a 'high' level of evidence regarding the risk of ototoxicity. The variant m.1095T>C has a 'moderate' level of evidence. The search for these variants can be performed in the laboratory if the administration of aminoglycosides can be delayed after obtaining the result. However, if the treatment is urgent, there is currently no rapid test available in France (a 'point-of-care' test is authorized in Great Britain). RNPGx considers: (1) the search for the m.1555A>G, m.1494C>T variants as 'highly recommended' and the m.1095T>C variant as 'moderately recommended' before the administration of an aminoglycoside (if compatible with the medical context). It should be noted that the level of heteroplasmy detected does not modify the recommendation; (2) pharmacogenetic analysis is currently not feasible in situations of short-term aminoglycoside administration, in the absence of an available analytical solution (rapid test to be evaluated in France); (3) the retrospective analysis in case of aminoglycoside-induced ototoxicity is 'recommended'; (4) analysis of relatives is 'recommended'. Through this summary, RNPGx proposes an updated review of the MT-RNR1-aminoglycoside gene-drug pair to serve as a basis for adapting practices regarding pharmacogenetic analysis related to aminoglycoside treatment.
Collapse
Affiliation(s)
- Louis Lebreton
- Département de biochimie, hôpital Pellegrin, centre hospitalier universitaire de Bordeaux, 33000 Bordeaux, France.
| | - Benjamin Hennart
- Unité fonctionnelle de toxicologie, CHU de Lille, 59037 Lille, France
| | - Sarah Baklouti
- Laboratoire de pharmacocinétique et toxicologie, institut fédératif de biologie, CHU de Toulouse, 31300 Toulouse, France; INTHERES, Inrae, ENVT, université de Toulouse, 31300 Toulouse, France
| | - Aurélien Trimouille
- Inserm U1211, Rare Diseases: Genetics and Metabolism (MRGM), Bordeaux University, Bordeaux, France; Reference Centre: Maladies Mitochondriales de l'Enfant à l'Adulte (CARAMMEL), University Hospital of Bordeaux, Bordeaux, France; Pathology Department, University Hospital of Bordeaux, 33000 Bordeaux, France
| | | | - Laurent Becquemont
- Inserm UMR 1018, CESP, MOODS Team, faculté de médecine, université Paris-Saclay, 94275 Le Kremlin-Bicêtre, France; Centre de recherche clinique, hôpital de Bicêtre, hôpitaux universitaires Paris-Saclay, Assistance publique-Hôpitaux de Paris, 94275 Le Kremlin-Bicêtre, France
| | - Claire-Marie Dhaenens
- Inserm, U1172 - LilNCog - Lille Neuroscience & Cognition, University of Lille, CHU de Lille, 59000 Lille, France
| | - Nicolas Picard
- Service de pharmacologie, toxicologie et pharmacovigilance, centre de biologie et de recherche en santé (CBRS), CHU de Limoges, 87042 Limoges, France
| |
Collapse
|
2
|
Roger C, Louart B, Elotmani L, Barton G, Escobar L, Koulenti D, Lipman J, Leone M, Muller L, Boutin C, Amour J, Banakh I, Cousson J, Bourenne J, Constantin JM, Albanese J, Roberts JA, Lefrant JY. An international survey on aminoglycoside practices in critically ill patients: the AMINO III study. Ann Intensive Care 2021; 11:49. [PMID: 33740157 PMCID: PMC7979853 DOI: 10.1186/s13613-021-00834-4] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/29/2020] [Accepted: 03/05/2021] [Indexed: 12/25/2022] Open
Abstract
BACKGROUND While aminoglycosides (AG) have been used for decades, debate remains on their optimal dosing strategy. We investigated the international practices of AG usage specifically regarding dosing and therapeutic drug monitoring (TDM) in critically ill patients. We conducted a prospective, multicentre, observational, cohort study in 59 intensive-care units (ICUs) in 5 countries enrolling all ICU patients receiving AG therapy for septic shock. RESULTS We enrolled 931 septic ICU patients [mean ± standard deviation, age 63 ± 15 years, female 364 (39%), median (IQR) SAPS II 51 (38-65)] receiving AG as part of empirical (761, 84%) or directed (147, 16%) therapy. The AG used was amikacin in 614 (66%), gentamicin in 303 (33%), and tobramycin in 14 (1%) patients. The median (IQR) duration of therapy was 2 (1-3) days, the number of doses was 2 (1-2), the median dose was 25 ± 6, 6 ± 2, and 6 ± 2 mg/kg for amikacin, gentamicin, and tobramycin respectively, and the median dosing interval was 26 (23.5-43.5) h. TDM of Cmax and Cmin was performed in 437 (47%) and 501 (57%) patients, respectively, after the first dose with 295 (68%) patients achieving a Cmax/MIC > 8 and 353 (71%) having concentrations above Cmin recommended thresholds. The ICU mortality rate was 27% with multivariable analysis showing no correlation between AG dosing or pharmacokinetic/pharmacodynamic target attainment and clinical outcomes. CONCLUSION Short courses of high AG doses are mainly used in ICU patients with septic shock, although wide variability in AG usage is reported. We could show no correlation between PK/PD target attainment and clinical outcome. Efforts to optimize the first AG dose remain necessary. Trial registration Clinical Trials, NCT02850029, registered on 29th July 2016, retrospectively registered, https://www.clinicaltrials.gov.
Collapse
Affiliation(s)
- Claire Roger
- Department of Intensive Care Medicine, Division of Anesthesiology, Intensive Care, Pain and Emergency Medicine, Nîmes University Hospital, Place du Professeur Robert Debré, 30 029, Nîmes cedex 9, France. .,Equipe D, Caractéristiques Féminines Des Interfaces Vasculaires (IMAGINE), Faculté de Médecine, Univ Montpellier, 2992, Montpellier, France.
| | - Benjamin Louart
- Department of Intensive Care Medicine, Division of Anesthesiology, Intensive Care, Pain and Emergency Medicine, Nîmes University Hospital, Place du Professeur Robert Debré, 30 029, Nîmes cedex 9, France.,Equipe D, Caractéristiques Féminines Des Interfaces Vasculaires (IMAGINE), Faculté de Médecine, Univ Montpellier, 2992, Montpellier, France
| | - Loubna Elotmani
- Department of Intensive Care Medicine, Division of Anesthesiology, Intensive Care, Pain and Emergency Medicine, Nîmes University Hospital, Place du Professeur Robert Debré, 30 029, Nîmes cedex 9, France.,Equipe D, Caractéristiques Féminines Des Interfaces Vasculaires (IMAGINE), Faculté de Médecine, Univ Montpellier, 2992, Montpellier, France
| | - Greg Barton
- St Helens and Knowsley Hospitals NHS Trust, Liverpool, UK
| | - Leslie Escobar
- Faculty of Medicine, Universidad de Chile, Santiago, Chile
| | - Despoina Koulenti
- The University of Queensland Centre for Clinical Research, The University of Queensland, Brisbane, Australia.,Second Critical Care Department, Attikon University Hospital, Athens, Greece
| | - Jeffrey Lipman
- Equipe D, Caractéristiques Féminines Des Interfaces Vasculaires (IMAGINE), Faculté de Médecine, Univ Montpellier, 2992, Montpellier, France.,The University of Queensland Centre for Clinical Research, The University of Queensland, Brisbane, Australia.,Department of Intensive Care Medicine, Royal Brisbane and Women's Hospital, Brisbane, Australia
| | - Marc Leone
- Department of Anesthesiology and Intensive Care Medicine, University Hospital of Marseille, Marseille, France
| | - Laurent Muller
- Department of Intensive Care Medicine, Division of Anesthesiology, Intensive Care, Pain and Emergency Medicine, Nîmes University Hospital, Place du Professeur Robert Debré, 30 029, Nîmes cedex 9, France.,Equipe D, Caractéristiques Féminines Des Interfaces Vasculaires (IMAGINE), Faculté de Médecine, Univ Montpellier, 2992, Montpellier, France
| | - Caroline Boutin
- Department of Intensive Care Medicine, Division of Anesthesiology, Intensive Care, Pain and Emergency Medicine, Nîmes University Hospital, Place du Professeur Robert Debré, 30 029, Nîmes cedex 9, France
| | - Julien Amour
- Institute of Perfusion, Critical Care Medicine and Anesthesiology in Cardiac Surgery (IPRA), Hôpital Privé Jacques Cartier, Massy, France
| | | | - Joel Cousson
- Department of Anesthesiology and Intensive Care Medicine, University Hospital of Reims, Reims, France
| | - Jeremy Bourenne
- Department of Emergency and Intensive Care Medicine, University Hospital of Marseille, Hôpital de La Timone, Marseille, France
| | - Jean-Michel Constantin
- Department of Anesthesiology and Intensive Care Medicine, University Hospital of Clermont-Ferrand, Clermont-Ferrand, France
| | - Jacques Albanese
- Department of Anesthesiology and Intensive Care Medicine, University Hospital of Marseille, Hôpital de La Conception, Marseille, France
| | - Jason A Roberts
- Equipe D, Caractéristiques Féminines Des Interfaces Vasculaires (IMAGINE), Faculté de Médecine, Univ Montpellier, 2992, Montpellier, France.,The University of Queensland Centre for Clinical Research, The University of Queensland, Brisbane, Australia.,Department of Intensive Care Medicine, Royal Brisbane and Women's Hospital, Brisbane, Australia.,Pharmacy Department, Royal Brisbane and Women's Hospital, Brisbane, Australia
| | - Jean-Yves Lefrant
- Department of Intensive Care Medicine, Division of Anesthesiology, Intensive Care, Pain and Emergency Medicine, Nîmes University Hospital, Place du Professeur Robert Debré, 30 029, Nîmes cedex 9, France.,Equipe D, Caractéristiques Féminines Des Interfaces Vasculaires (IMAGINE), Faculté de Médecine, Univ Montpellier, 2992, Montpellier, France
| | | |
Collapse
|
3
|
Onyango EJ, Okalebo F, Oluka M, Kinuthia R, Achieng L, Godman B, Kurdi A. Evaluation of the clinical practice of aminoglycoside use in paediatric patients in Kenya: findings and implications for lower-middle income countries. JAC Antimicrob Resist 2020; 2:dlz087. [PMID: 34222978 PMCID: PMC8210310 DOI: 10.1093/jacamr/dlz087] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2019] [Revised: 11/28/2019] [Accepted: 11/29/2019] [Indexed: 01/06/2023] Open
Abstract
OBJECTIVES To evaluate the practice of aminoglycoside use/monitoring in Kenya and explore healthcare worker (HCW) perceptions of aminoglycoside monitoring to identify gaps and opportunities for future improvements, given the low therapeutic index of aminoglycosides. METHODS This was a two-phase study whereby we reviewed patients' medical records at Kenyatta National Hospital (October-December 2016) in Phase 1 and interviewed HCWs face to face in Phase 2. Outcome measures included describing and evaluating the practice of aminoglycoside use and monitoring and compliance to guidelines. Data were analysed using descriptive and inferential analysis. RESULTS Overall, out of the 2318 patients admitted, 192 patients (8.3%) were prescribed an aminoglycoside, of which 102 (53.1%) had aminoglycoside doses that did not conform to national guidelines. Aminoglycoside-related adverse effects were suspected in 65 (33.9%) patients. Monitoring of aminoglycoside therapy was performed in only 17 (8.9%) patients, with no therapeutic drug monitoring (TDM), attributed mainly to knowledge and skill gaps and lack of resources. Out of the 28 recruited HCWs, 18 (64.3%) needed training in how to perform and interpret TDM results. CONCLUSIONS The practice of using and monitoring aminoglycosides was suboptimal, raising concerns around potential avoidable harm to patients. The identified gaps could form the basis for developing strategies to improve the future use of aminoglycosides, not only in Kenya but also in other countries with similar settings and resources.
Collapse
Affiliation(s)
| | - Faith Okalebo
- University of Nairobi, PO Box 19676 NAIROBI - 00202 KNH, Nairobi, Kenya
| | - Margaret Oluka
- University of Nairobi, PO Box 19676 NAIROBI - 00202 KNH, Nairobi, Kenya
| | - Rosaline Kinuthia
- Kenyatta National Hospital, PO Box 20723, Hospital Rd, Nairobi, Kenya
| | - Loice Achieng
- University of Nairobi, PO Box 19676 NAIROBI - 00202 KNH, Nairobi, Kenya
| | - Brian Godman
- Strathclyde Institute of Pharmacy and Biomedical Science, University of Strathclyde, 16 Richmond Street, Glasgow G1 1XQ, Scotland
- Division of Public Health Pharmacy and Management, School of Pharmacy, Sefako Makgatho Health Sciences University, Ga-Rankuwa, Pretoria, South Africa
- Division of Clinical Pharmacology, Karolinska Institute, Karolinska University Hospital Huddinge, Stockholm, Sweden
| | - Amanj Kurdi
- Strathclyde Institute of Pharmacy and Biomedical Science, University of Strathclyde, 16 Richmond Street, Glasgow G1 1XQ, Scotland
- Department of Pharmacology and Toxicology, College of Pharmacy, Hawler Medical University, Erbil, Iraq
| |
Collapse
|
4
|
DVOŘÁČKOVÁ E, PÁVEK P, KOVÁČOVÁ B, RYCHLÍČKOVÁ J, SUCHOPÁR O, HOJNÝ M, TEBBENS JD, VLČEK J. Is Computer-Assisted Aminoglycoside Dosing Managed by a Pharmacist a Safety Tool of Pharmacotherapy? Physiol Res 2019; 68:S87-S96. [DOI: 10.33549/physiolres.934329] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023] Open
Abstract
This pilot prospective study verified the hypothesis that use of computer-assisted therapeutic drug monitoring of aminoglycosides by pharmacists leads to better safety therapeutic outcomes and cost avoidance than only concentration measurement and dose adjustments based on a physician’s experience. Two groups of patients were enrolled according to the technique of monitoring. Patients (Group 1, n=52) underwent monitoring by a pharmacist using pharmacokinetic software. In a control group (Group 2, n=11), plasma levels were measured but not interpreted by the pharmacist, only by physicians. No statistically significant differences were found between the groups in factors influenced by therapy. However, the results are not statistically significant but a comparison of the groups showed a clear trend towards safety and cost avoidance, thus supporting therapeutic drug monitoring. Safety limits were achieved in 76 % and 63 % of cases in Groups 1 and 2, respectively. More patients achieved both concentrations (peak and trough) with falling eGFR in Group 1. In present pilot study, the pharmacist improved the care of patients on aminoglycoside therapy. A larger study is needed to demonstrate statistically significantly improved safety and cost avoidance of aminoglycoside therapy monitoring by the pharmacist using pharmacokinetic software.
Collapse
Affiliation(s)
- E. DVOŘÁČKOVÁ
- Department of Social and Clinical Pharmacy, Faculty of Pharmacy, Charles University, Hradec Králové, Czech Republic
| | | | | | | | | | | | | | | |
Collapse
|
5
|
Ben Romdhane H, Ben Fredj N, Chaabane A, Ben Aicha S, Chadly Z, Ben Fadhel N, Boughattas N, Aouam K. Interest of therapeutic drug monitoring of aminoglycosides administered by a monodose regimen. Nephrol Ther 2019; 15:110-114. [PMID: 30660586 DOI: 10.1016/j.nephro.2018.08.004] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2018] [Revised: 08/24/2018] [Accepted: 08/28/2018] [Indexed: 10/27/2022]
Abstract
BACKGROUND Although the once-daily regimen of aminoglycosides (AG) is considered as predominantly used by many centers, the level of evidence of Therapeutic Drug Monitoring (TDM) of AG in cases of once-daily has not been clearly defined. The objective of this study is to evaluate the impact of TDM in achievement or maintaining target serum concentrations in patients receiving once-daily administration of AG. METHODS We performed a retrospective analysis of data from patients having received a once daily amikacin or gentamicin and underwent routine TDM. A longitudinal follow up was performed. Data were analyzed according to the adhesion or not to recommendations. A logistic regression was performed in order to evaluate the effect of covariates (age, gender, weight, creatinine clearance [CLcr], TDM-based dose adjustment, weighted dose of AG) on the achievement of non-toxic Cmin. RESULTS A total 437 blood samples issued from 324 patients were analyzed. The cut-off value of Clcr associated with a risk of toxic Cmin was≤41.66mL/min (OR: 11.29; 95%CI: 7.21-17.61; P<0.0001). Eighty-eight patients (27.1%) have at least two sampling points. The univariate analysis showed that the age, weight, CLcr and TDM-based dose adjustment were found to be significant factors in the achievement of non-toxic Cmin. In multivariate analysis, only TDM-based dose adjustment remains a significant factor in the achievement of non-toxic Cmin (OR: 6.66; 95%CI: 2.26-19.63; P=0.0006). CONCLUSION Our study demonstrates the usefulness of TDM-based dosing adjustment of AG antibiotics in achieving nontoxic trough concentrations, particularly in critically ill patients, as they are prone to a renal impairment.
Collapse
Affiliation(s)
- Haifa Ben Romdhane
- EPS Monastir, service de pharmacologie clinique, laboratoire de pharmacologie, faculté de médecine de Monastir, rue Avicenne, 5019 Monastir, Tunisia
| | - Nadia Ben Fredj
- EPS Monastir, service de pharmacologie clinique, laboratoire de pharmacologie, faculté de médecine de Monastir, rue Avicenne, 5019 Monastir, Tunisia.
| | - Amel Chaabane
- EPS Monastir, service de pharmacologie clinique, laboratoire de pharmacologie, faculté de médecine de Monastir, rue Avicenne, 5019 Monastir, Tunisia
| | - Sana Ben Aicha
- EPS Monastir, service de pharmacologie clinique, laboratoire de pharmacologie, faculté de médecine de Monastir, rue Avicenne, 5019 Monastir, Tunisia
| | - Zohra Chadly
- EPS Monastir, service de pharmacologie clinique, laboratoire de pharmacologie, faculté de médecine de Monastir, rue Avicenne, 5019 Monastir, Tunisia
| | - Najeh Ben Fadhel
- EPS Monastir, service de pharmacologie clinique, laboratoire de pharmacologie, faculté de médecine de Monastir, rue Avicenne, 5019 Monastir, Tunisia
| | - Naceur Boughattas
- EPS Monastir, service de pharmacologie clinique, laboratoire de pharmacologie, faculté de médecine de Monastir, rue Avicenne, 5019 Monastir, Tunisia
| | - Karim Aouam
- EPS Monastir, service de pharmacologie clinique, laboratoire de pharmacologie, faculté de médecine de Monastir, rue Avicenne, 5019 Monastir, Tunisia
| |
Collapse
|
6
|
Boidin C, Jenck S, Bourguignon L, Torkmani S, Roussey-Jean A, Ledochowski S, Marry L, Ammenouche N, Dupont H, Marçon F, Allaouchiche B, Bohé J, Lepape A, Goutelle S, Friggeri A. Determinants of amikacin first peak concentration in critically ill patients. Fundam Clin Pharmacol 2018; 32:669-677. [PMID: 29660162 DOI: 10.1111/fcp.12374] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2018] [Revised: 03/26/2018] [Accepted: 04/09/2018] [Indexed: 11/29/2022]
Abstract
Amikacin antimicrobial effect has been correlated with the ratio of the peak concentration (Cmax ) to the minimum inhibitory concentration. A target Cmax ≥ 60-80 mg/L has been suggested. It has been shown that such target is not achieved in a large proportion of critically ill patients in intensive care units. A retrospective analysis was performed to examine the determinants of Cmax ≥ 80 mg/L on the first peak in 339 critically ill patients treated by amikacin. The influence of available variables on Cmax target attainment was analyzed using a classification and regression tree (CART) and logistic regression. Mean Cmax in the 339 patients was 73.0 ± 23.9 mg/L, with a target attainment rate (TAR, Cmax ≥ 80 mg/L) of 37.5%. In CART analysis, the strongest predictor of amikacin target peak attainment was dose per kilogram of lean body weight (dose/LBW). TAR was 60.1% in patients with dose/LBW ≥ 37.8 vs. 19.9% in patients with lower dose/LBW (OR = 6.0 (95% CI: 3.6-10.2)). Renal function was a secondary predictor of Cmax . Logistic regression analysis identified dose per kilogram of ideal body weight (OR = 1.13 (95% CI: 1.09-1.17)) and creatinine clearance (OR = 0.993 (95% CI: 0.988-0.998)) as predictors of target peak achievement. Based on our results, an amikacin dose ≥ 37.8 mg/kg of LBW should be used to optimize the attainment of Cmax ≥ 80 mg/L after the first dose in critically ill patients. An even higher dose may be necessary in patients with normal renal function.
Collapse
Affiliation(s)
- Clément Boidin
- Groupement Hospitalier Nord, Service de Pharmacie, Hôpital Pierre Garraud, Hospices Civils de Lyon, 136 rue du Commandant Charcot, 69322, LyonCedex 5, France.,Laboratoire de Biométrie et Biologie Évolutive, Université Claude Bernard Lyon 1, UMR CNRS 5558, University of Lyon, Bât. Grégor Mendel, 43 bd du 11 novembre 1918, 69622, Villeurbanne Cedex, France
| | - Sophie Jenck
- Groupement Hospitalier Sud, Service d'Anesthésie et de Réanimation, Hospices Civils de Lyon, 165 Chemin du Grand Revoyet, 69495, Pierre-Bénite, France
| | - Laurent Bourguignon
- Groupement Hospitalier Nord, Service de Pharmacie, Hôpital Pierre Garraud, Hospices Civils de Lyon, 136 rue du Commandant Charcot, 69322, LyonCedex 5, France.,Laboratoire de Biométrie et Biologie Évolutive, Université Claude Bernard Lyon 1, UMR CNRS 5558, University of Lyon, Bât. Grégor Mendel, 43 bd du 11 novembre 1918, 69622, Villeurbanne Cedex, France.,ISPB - Faculté de Pharmacie de Lyon, Université Claude Bernard Lyon 1, University of Lyon, 8 Avenue Rockefeller, 69003, Lyon, France
| | - Sejad Torkmani
- Groupement Hospitalier Sud, Service d'Anesthésie et de Réanimation, Hospices Civils de Lyon, 165 Chemin du Grand Revoyet, 69495, Pierre-Bénite, France
| | - Aurore Roussey-Jean
- Groupement Hospitalier Sud, Service d'Anesthésie et de Réanimation, Hospices Civils de Lyon, 165 Chemin du Grand Revoyet, 69495, Pierre-Bénite, France
| | - Stanislas Ledochowski
- Groupement Hospitalier Sud, Service d'Anesthésie et de Réanimation, Hospices Civils de Lyon, 165 Chemin du Grand Revoyet, 69495, Pierre-Bénite, France
| | - Lucie Marry
- Service d'Anesthésie et de Réanimation, Centre Hospitalier Universitaire Amiens-Picardie, Site Sud, 80054, Amiens Cedex 1, France
| | - Nacim Ammenouche
- Service d'Anesthésie et de Réanimation, Centre Hospitalier Universitaire Amiens-Picardie, Site Sud, 80054, Amiens Cedex 1, France
| | - Hervé Dupont
- Service d'Anesthésie et de Réanimation, Centre Hospitalier Universitaire Amiens-Picardie, Site Sud, 80054, Amiens Cedex 1, France
| | - Frédéric Marçon
- Service de Pharmacie, Centre Hospitalier Universitaire Amiens-Picardie, Site Sud, 80054, Amiens Cedex 1, France
| | - Bernard Allaouchiche
- Groupement Hospitalier Sud, Service d'Anesthésie et de Réanimation, Hospices Civils de Lyon, 165 Chemin du Grand Revoyet, 69495, Pierre-Bénite, France.,Faculté de Médecine Lyon Sud-Charles Mérieux, Université Claude Bernard Lyon 1, University of Lyon, 165 Rue du Petit Revoyet, 69600, Oullins, France
| | - Julien Bohé
- Groupement Hospitalier Sud, Service d'Anesthésie et de Réanimation, Hospices Civils de Lyon, 165 Chemin du Grand Revoyet, 69495, Pierre-Bénite, France.,Faculté de Médecine Lyon Sud-Charles Mérieux, Université Claude Bernard Lyon 1, University of Lyon, 165 Rue du Petit Revoyet, 69600, Oullins, France
| | - Alain Lepape
- Groupement Hospitalier Sud, Service d'Anesthésie et de Réanimation, Hospices Civils de Lyon, 165 Chemin du Grand Revoyet, 69495, Pierre-Bénite, France.,Laboratoire des Pathogènes Émergents, Université Claude Bernard Lyon 1, UMR CNRS 5308, Inserm U1111, Centre International de Recherche en Infectiologie, University of Lyon, 21 avenue Tony Garnier, 69365, Lyon cedex 07, France
| | - Sylvain Goutelle
- Groupement Hospitalier Nord, Service de Pharmacie, Hôpital Pierre Garraud, Hospices Civils de Lyon, 136 rue du Commandant Charcot, 69322, LyonCedex 5, France.,Laboratoire de Biométrie et Biologie Évolutive, Université Claude Bernard Lyon 1, UMR CNRS 5558, University of Lyon, Bât. Grégor Mendel, 43 bd du 11 novembre 1918, 69622, Villeurbanne Cedex, France.,ISPB - Faculté de Pharmacie de Lyon, Université Claude Bernard Lyon 1, University of Lyon, 8 Avenue Rockefeller, 69003, Lyon, France
| | - Arnaud Friggeri
- Groupement Hospitalier Sud, Service d'Anesthésie et de Réanimation, Hospices Civils de Lyon, 165 Chemin du Grand Revoyet, 69495, Pierre-Bénite, France.,Faculté de Médecine Lyon Sud-Charles Mérieux, Université Claude Bernard Lyon 1, University of Lyon, 165 Rue du Petit Revoyet, 69600, Oullins, France.,Laboratoire des Pathogènes Émergents, Université Claude Bernard Lyon 1, UMR CNRS 5308, Inserm U1111, Centre International de Recherche en Infectiologie, University of Lyon, 21 avenue Tony Garnier, 69365, Lyon cedex 07, France
| |
Collapse
|
7
|
Concentrations systémiques d’antibiotiques potentiellement toxiques après administration par pansement imprégné chez un patient brûlé : à propos d’un cas clinique. Therapie 2016; 71:483-486. [DOI: 10.1016/j.therap.2016.03.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2016] [Accepted: 03/31/2016] [Indexed: 11/19/2022]
|
8
|
McLawhon RW. Guidelines for the Monitoring of Vancomycin, Aminoglycosides and Certain Antibiotics. Ther Drug Monit 2012. [DOI: 10.1016/b978-0-12-385467-4.00010-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/04/2023]
|